Last reviewed · How we verify
Teriparatide treatment in osteoporotic patients
At a glance
| Generic name | Teriparatide treatment in osteoporotic patients |
|---|---|
| Sponsor | Shinshu University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture (NA)
- Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients (PHASE4)
- VERtebral Fracture Treatment Comparisons in Osteoporotic Women (PHASE4)
- Secondary Prevention of Osteoporotic Fractures: a Multiple Center Fracture Liaison Service in Greece
- Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |